Explore

Rapid Read Rapid Read
Study Suggests Timing of Cancer Treatment Influences Effectiveness

Study Suggests Timing of Cancer Treatment Influences Effectiveness

A new study led by researchers in China, published in Nature Medicine, indicates that the timing of cancer treatment can significantly affect its success. Patients with non-small-cell lung cancer who received immunotherapy treatments before 3 p.m. experienced longer progression-free survival and overall survival compared to those treated later in the day. The study builds on previous observational research suggesting that the body's circadian rhythms influence immune system effectiveness, potentially impacting the efficacy of cancer treatments.
Rapid Read Rapid Read
Kelun-Biotech's Sacituzumab Tirumotecan Approved for New Breast Cancer Indication in China

Kelun-Biotech's Sacituzumab Tirumotecan Approved for New Breast Cancer Indication in China

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. has announced the approval of a new indication for its TROP2-directed antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), by the National Medical Products Administration (NMPA) of China. This approval is for the treatment of adult patients with unresectable or metastatic HR+/HER2- breast cancer who have previously received endocrine therapy and at least one line of chemotherapy. The approval is based on positive results from the Phase III OptiTROP-Breast02 study, which demonstrated a significant increase in progression-free survival compared to chemotherapy. Sac-TMT is now approved for four indications in China, marking a significant milestone for Kelun-Biotech.
Rapid Read Rapid Read
Baylor College of Medicine Uncovers Mechanism Behind Triple Negative Breast Cancer Metastasis

Baylor College of Medicine Uncovers Mechanism Behind Triple Negative Breast Cancer Metastasis

Researchers at Baylor College of Medicine have identified a mechanism that allows triple negative breast cancer (TNBC) cells to metastasize more effectively. The study, published in Nature Communications, reveals that TNBC cells use a component of the extracellular matrix, hyaluronan (HA), to form stable clusters. These clusters are more likely to survive in the bloodstream and seed new tumors in other parts of the body. The research highlights that TNBC cells produce large amounts of HA, which acts as a 'sticky coat' enabling cell-cell interactions even in the absence of typical adhesion molecules. This discovery opens up potential avenues for developing treatments aimed at preventing or reducing metastasis by targeting the HA and CD44 interaction.
Trendline Trendline
K36 Therapeutics Completes Initial Dosing in Prostate Cancer Trial, Appoints New CMO

K36 Therapeutics Completes Initial Dosing in Prostate Cancer Trial, Appoints New CMO

K36 Therapeutics Completes Initial Dosing in Prostate Cancer Trial, Appoints New CMO
Rapid Read Rapid Read
Glioblastoma Patient's Survival Highlights Potential of New Treatment Trial

Glioblastoma Patient's Survival Highlights Potential of New Treatment Trial

Becca Valle, diagnosed with glioblastoma, a typically fatal brain cancer, has survived four years post-diagnosis, defying the odds. Her survival is attributed to participating in a clinical trial at the University of Maryland, which tested a focused ultrasound technique to temporarily open the blood-brain barrier, allowing chemotherapy to penetrate the brain more effectively. The trial showed promising results, with a significant portion of participants surviving longer than expected. The research is ongoing, with hopes of developing an FDA-approved device to enhance treatment options for glioblastoma patients.
Rapid Read Rapid Read
Becca Valle's Remarkable Survival Story After Glioblastoma Diagnosis

Becca Valle's Remarkable Survival Story After Glioblastoma Diagnosis

Becca Valle, a woman who initially experienced severe headaches, was diagnosed with glioblastoma, a highly aggressive brain tumor. Despite the grim prognosis, Valle participated in a clinical trial that involved using focused ultrasound to temporarily open the blood-brain barrier, allowing chemotherapy to be more effective. This innovative approach, led by Dr. Graeme Woodworth at the University of Maryland Medical Center, showed promising results, with Valle being one of the few patients to survive beyond the typical five-year mark. The trial's success has sparked further research into non-invasive methods to treat brain cancers and the potential development of devices to aid in such treatments.
Rapid Read Rapid Read
New CAR-T Therapy Targets Cancer Cells Without Immune Suppression

New CAR-T Therapy Targets Cancer Cells Without Immune Suppression

Researchers have developed a new CAR-T-cell therapy, known as CART4-34, which effectively targets cancer cells without the severe side effect of immune system suppression. This therapy focuses on B cell receptors carrying the IGHV4-34 gene, which is prevalent in cancer cells but rare in healthy cells. Unlike conventional CD19 CAR-T therapies that destroy all cells carrying the CD19 molecule, leading to immune suppression, CART4-34 spares healthy B cells. This advancement was demonstrated in genetically modified mice with diffuse large B cell lymphoma, where CART4-34 was as effective as CD19 CAR-T therapy in destroying cancer cells. The therapy also holds potential for treating autoimmune conditions like lupus, where antibodies targeting IGHV4-34 are linked to more aggressive disease forms.
Rapid Read Rapid Read
Doctors Urge Americans to Prioritize Cancer Screenings Amid Low Participation Rates

Doctors Urge Americans to Prioritize Cancer Screenings Amid Low Participation Rates

Medical professionals are emphasizing the importance of regular cancer screenings for Americans, as statistics reveal that more than half of the population does not adhere to recommended screening schedules. This is despite the fact that approximately one in three individuals in the U.S. will be diagnosed with cancer at some point in their lives. The call to action is driven by concerns that skipping these screenings could lead to late-stage cancer diagnoses, which are often more difficult to treat and have poorer outcomes. The report highlights the need for increased public awareness and education on the benefits of early detection through routine screenings.
Rapid Read Rapid Read
Field Medical Unveils Breakthrough Field PULSE Trial Data at AF Symposium 2026

Field Medical Unveils Breakthrough Field PULSE Trial Data at AF Symposium 2026

Field Medical, Inc., a clinical-stage medical technology company, has presented significant findings from its Field PULSE study at the 31st Annual International AF Symposium 2026 in Boston. The study focuses on a novel pulsed field ablation (PFA) technology designed to treat complex cardiac arrhythmias. Utilizing the FieldForce Ablation System, the study demonstrated the ability to perform instantaneous ablation through high-voltage waveforms, achieving rapid point-by-point energy delivery without the need for prolonged tissue-catheter contact. The trial was highlighted as a Late Breaking Clinical Trial, underscoring its importance in the field. Key findings include the creation of lesions in under 200 milliseconds and a median bilateral pulmonary vein isolation time of 12.5 minutes, with no device-related serious adverse events reported.
Rapid Read Rapid Read
Vitamin D Supplementation Linked to Lower Blood Sugar in Prediabetes Study

Vitamin D Supplementation Linked to Lower Blood Sugar in Prediabetes Study

A recent study suggests that vitamin D supplementation may help lower blood sugar levels in individuals with prediabetes. The research, published in the Journal of the Endocrine Society, analyzed data from 10 clinical trials involving nearly 4,500 participants. The findings indicate that 18.5% of those who took vitamin D achieved normal blood sugar levels, compared to 14% who took a placebo. Experts believe that vitamin D may support blood sugar management and reduce insulin resistance, a precursor to type 2 diabetes. However, the study's authors caution that vitamin D should not replace medical treatments but could be part of a broader diabetes prevention strategy.
Trendline Trendline
Eikon and Veradermics Complete IPOs, Salspera Joins Nasdaq Queue

Eikon and Veradermics Complete IPOs, Salspera Joins Nasdaq Queue

Eikon and Veradermics Complete IPOs, Salspera Joins Nasdaq Queue
Rapid Read Rapid Read
Quebec's Public Reimbursement of Jemperli Plus Chemotherapy Expands Access for Endometrial Cancer Patients

Quebec's Public Reimbursement of Jemperli Plus Chemotherapy Expands Access for Endometrial Cancer Patients

Quebec has become the first Canadian province to publicly reimburse Jemperli (dostarlimab for injection) in combination with chemotherapy for treating adult patients with primary advanced or first recurrent endometrial cancer. This decision, announced by GSK, marks a significant milestone in improving access to treatment for eligible patients. The reimbursement is facilitated through the Régie de l'assurance maladie du Québec (RAMQ), removing financial barriers and enabling timely access to this standard-of-care combination therapy. The decision follows Health Canada's approval of the indication in April 2025, based on the RUBY phase III trial results, which demonstrated significant survival benefits. This move is expected to set a positive precedent for other provinces in Canada.